- Home
- TNYA vs CNTB Comparison
TNYA vs CNTB Comparison
Compare TNYA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNYA | CNTB |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 140.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TNYA | CNTB |
|---|---|---|
| Price | $0.38 | $0.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $3.20 | ★ $5.88 |
| AVG Volume (30 Days) | ★ 3.9M | 1.5M |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.96 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | $11,291.47 |
| Revenue Next Year | N/A | $74.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $0.73 |
| 52 Week High | $1.70 | $3.82 |
Technical Indicators
Market Signals| Indicator | TNYA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 28.09 | 34.09 |
| Support Level | $0.36 | N/A |
| Resistance Level | $0.80 | $2.84 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 13.26 | 5.28 |
Price Performance
Historical ComparisonAbout TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.